Next Article in Journal
Infection Control in the Era of COVID-19: A Narrative Review
Next Article in Special Issue
Molecular Determinants of Ethionamide Resistance in Clinical Isolates of Mycobacterium tuberculosis
Previous Article in Journal
Therapeutic Potential of Sitafloxacin as a New Drug Candidate for Helicobacter Eradication in Korea: An In Vitro Culture-Based Study
Previous Article in Special Issue
The Epistatic Landscape of Antibiotic Resistance of Different Clades of Mycobacterium tuberculosis

Genetic Profile of Linezolid-Resistant M. tuberculosis Clinical Strains from Moscow

Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia
The Moscow Research and Clinical Center for Tuberculosis Control, Moscow Government Health Department, 107014 Moscow, Russia
Author to whom correspondence should be addressed.
Antibiotics 2021, 10(10), 1243;
Received: 9 September 2021 / Revised: 6 October 2021 / Accepted: 11 October 2021 / Published: 13 October 2021
Background: Linezolid, bedaquiline, and newer fluoroquinolones are currently placed as priority Group A drugs for the treatment of drug-resistant tuberculosis. The number of reported linezolid-resistant clinical strains is still low, and the correlation of molecular determinants with phenotype is not perfect. Methods: We determined the linezolid MICs for clinical isolates from the Moscow region and identified mutations in rplC and rrl genes. Results: All 16 linezolid-resistant isolates had previously reported mutations in the rplC or rrl loci, and 13 of them bore a RplC C154R substitution. Detection of this substitution in a heteroresistant state was not successful, probably, due to the more stable DNA secondary structure of the mutated fragment, which precludes its amplification in mixes with the wild-type DNA. Strains with an rplC mutation had higher linezolid MIC compared to isolates with rrl mutations. Conclusions: Linezolid resistance mostly emerged during treatment with the latest regimen. Three primary cases with linezolid resistance question the possible transmission of totally drug-resistant tuberculosis in the Moscow region, which demands further investigation. View Full-Text
Keywords: tuberculosis; drug-resistance; linezolid tuberculosis; drug-resistance; linezolid
Show Figures

Figure 1

MDPI and ACS Style

Ushtanit, A.; Mikhailova, Y.; Lyubimova, A.; Makarova, M.; Safonova, S.; Filippov, A.; Borisov, S.; Zimenkov, D. Genetic Profile of Linezolid-Resistant M. tuberculosis Clinical Strains from Moscow. Antibiotics 2021, 10, 1243.

AMA Style

Ushtanit A, Mikhailova Y, Lyubimova A, Makarova M, Safonova S, Filippov A, Borisov S, Zimenkov D. Genetic Profile of Linezolid-Resistant M. tuberculosis Clinical Strains from Moscow. Antibiotics. 2021; 10(10):1243.

Chicago/Turabian Style

Ushtanit, Anastasia, Yulia Mikhailova, Alexandra Lyubimova, Marina Makarova, Svetlana Safonova, Alexey Filippov, Sergey Borisov, and Danila Zimenkov. 2021. "Genetic Profile of Linezolid-Resistant M. tuberculosis Clinical Strains from Moscow" Antibiotics 10, no. 10: 1243.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop